IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]

Results from the HPTN 067 or ADAPT trial -- a study of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis for gay men in New York City and Bangkok, and heterosexual women in Cape Town -- add to the growing body of evidence about how best to use PrEP and how its protective effect may vary across population groups and with different dosing schedules, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

[Robert Grant, IAS 2015, July 20, 2015]

Robert Grant from the UCSF Gladstone Institutes presented an overview of the 11 HPTN 067 presentations -- which included comparisons of daily and intermittent Truvada dosing and qualitative analyses of PrEP user experiences -- at an IAS media briefing on PrEP, HIV treatment-as-prevention, and early antiretroviral therapy.

"While many participants preferred daily dosing, they wanted to be able to change their PrEP program and start and stop PrEP as they needed and as their sexual lives changed," Grant said. "People want guidance about how to start and stop PrEP as they move in and out of seasons of risk."

SEE ALSO:

IAS 2015: Non-Daily PrEP Provides Extra Options, But Adherence Often Better with Daily Dosing

IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study

8/20/15

Source

8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Media briefing, July 20, 2015.